Velpanat Tablet

Product Description

Velpanat is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for Ribavirin.

Natco has signed a non-exclusive licensing agreement with Gilead Sciences, Inc., to manufacture and sell generic versions of its chronic hepatitis C medicines in 101 developing countries.

• Mechanism of Action: The medicine works by lowering the amount of the hepatitis C virus in the body and eventually eliminating it from the bloodstream. Sofosbuvir inhibits the NS5B polymerase protein, while velpatasvir blocks the NS5A protein; both are crucial for the virus's replication and assembly.
• Efficacy: When used as prescribed, Velpanat has a high cure rate (over 90-95%) and is effective against all six main genotypes of the hepatitis C virus (pan-genotypic).
• Dosage and Administration: It is typically taken once a day as a whole tablet, with or without food, for a duration usually ranging from 12 to 24 weeks, depending on the patient's condition and medical history.
• Benefits: Successful treatment with Velpanat can significantly reduce liver inflammation and fibrosis, lowering the risk of severe complications like liver cirrhosis, liver failure, and liver cancer. 

• Prescription Only: Velpanat is a prescription drug and should only be used under the supervision and advice of a healthcare professional.
• Side Effects: Common side effects can include fatigue, headache, nausea, insomnia (trouble sleeping), and diarrhea.
• Drug Interactions: It is important to inform your doctor about all other medicines, supplements, or herbal products (like St. John's wort) you are taking, as some can interact with Velpanat and reduce its effectiveness or cause serious side effects, such as a dangerously slow heart rate when taken with amiodarone.
• Alcohol: Avoid or limit alcohol consumption during treatment, as it can worsen liver health and interfere with the medication's efficacy. 

Powerful Oral Therapy for Hepatitis C

Velpanat Tablet offers an effective oral solution for chronic Hepatitis C infection in adults. With its fixed-dose combination of Sofosbuvir and Velpatasvir, the medication targets diverse genotypes of HCV, providing broad-spectrum antiviral activity. Its user-friendly once-daily administration supports high adherence to therapy.


Quality and Safety Assured

Manufactured and marketed by Natco Pharma Ltd., Velpanat tablets adhere to stringent quality standards. The tablets are film-coated, odorless, and maintain stability when stored as directed. Patients are advised to use this medication under strict medical supervision, especially given potential side effects and contraindications.